NCT04347876

Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?

Outcome of COVID-19 Cases Admitted to Hospital and ICU With Positive Tuberculin Test: Can Previous BCG Alter the Prognosis?

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: Assiut University · Academic / Other
• Sex: All
• Age: 12 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

There is no evidence that the Bacille Calmette-Guérin vaccine (BCG) protects people against infection with COVID-19 virus. Two clinical trials addressing this question are underway, and WHO will evaluate the evidence when it is available. In the absence of evidence, WHO does not recommend BCG vaccination for the prevention of COVID-19. WHO continues to recommend neonatal BCG vaccination in countries or settings with a high incidence of tuberculosis. There is experimental evidence from both animal and human studies that the BCG vaccine has non-specific effects on the immune system. These effects have not been well characterized and their clinical relevance is unknown

Conditions

• COVID-19
• BCG Vaccination

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Tuberculin test	Test the delayed hypersensitivity reaction and immunity to previous BCG vaccination

Timeline

• Start date: 2020-04-11
• Primary completion: 2020-06-16
• Completion: 2020-06-30
• First posted: 2020-04-15
• Last updated: 2020-04-15

Locations

1 site across 1 country: Egypt